Barrett's esophagus


Also found in: Acronyms, Wikipedia.

Barrett's esophagus

Etymology: Norman R. Barrett, English surgeon, 1903-1979
a disorder of the lower esophagus marked by a benign ulcerlike lesion in columnar epithelium, resulting most often from chronic irritation of the esophagus by gastric reflux of acidic digestive juices. Major symptoms include dysphagia, decreased lower esophageal (LES) pressure, and heartburn. Symptoms may be relieved by eating frequent small meals, avoiding foods that produce gas, taking antacid medication, and elevating the head of the bed to prevent passive reflux when lying down. Treatment consists of proton pump inhibitors and H2 blockers. The lesion is considered premalignant, and surveillance endoscopy is performed to screen for esophageal cancer. Also called Barrett's syndrome.

Barrett's esophagus

Gastroenterology A condition estimated to occur in ± 2 million Americans, which develops in Pts with GERD Definition Replacement of normal stratified squamous epithelium with metaplastic, premalignant intestinal columnar epithelium in the distal esophagus, ± accompanied by peptic ulceration, typically a sequel to chronic reflex; the degree of dysplasia correlates with aneuploidy by flow cytometry Endoscopy BE changes include a proximal migration of the squamocolumnar Z-line, and patchy areas corresponding to single layered columnar cells in intimate contact with underlying blood vessels; although most Pts are adults, BE may affect children, suggesting BE has a congenital component; BE carries a ± 35-40-fold ↑ risk of esophageal adenoCA, which is almost invariably accompanied by dysplasia, and has a prognosis similar to that of epidermoid carcinoma–14.5% 5-yr survival Management-restore normal squamous epithelium Electrocoagulation, argon plasma coagulation, laser therapy, laser + antireflux surgery, photodynamic therapy; thermal ablation of metaplastic esophageal mucosa has fallen into disfavor Low-grade dysplasia Follow-up, possibly β-carotene High-grade dysplasia Esophagectomy; endoscopic mucosal ablation, photodynamic therapy

Patient discussion about Barrett's esophagus

Q. Cn barret esophagous be cured? I was diagnosed with barretts esophagus several years ago, and so far keeps on the routine follow up. I met some other guy with same condition and he told after his doctor prescribed him with some anti-reflux meds, in the last endoscopy they found normal esophagus, and that he thinks he's now cured. Is that possible?

A. Anti-reflux treatment may lower the risk of cancer a little, but it won't cure it, so there's still a need for refular follow-up.

More discussions about Barrett's esophagus
References in periodicals archive ?
We are pleased to have obtained FDA clearance to expand our indications for use to include Barrett's Esophagus with low grade dysplasia as an example of benign disease ablation as well as our present indication for Barrett's Esophagus with high grade dysplasia and malignant disease ablation," said Ellen Sheets MD, CEO and president of CSA Medical.
The company said truFreeze is now approved as a treatment option for Barrett's Esophagus and supports coverage decisions for truFreeze patient treatments.
Although Barrett's esophagus is a benign condition, the cells can become abnormal (dysplasia), and may eventually turn cancerous.
C2 Therapeutics was founded in 2007 to address the limitations of current Barrett's esophagus treatment options.
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
3 Barrett's esophagus, which affects more than 12 million American adults, develops as a result of chronic injury from gastroesophageal reflux disease (GERD).
The trouble with Barrett's esophagus is that it looks bland and might span over 10 cm (about 4 inches)," says Dr.
Barrett's esophagus (BE) is defined as a condition of the lower esophagus in which the normal squamous epithelium is replaced by columnar epithelium as a result of chronic gastroesophageal reflux (GERD) (1).
In future work, the researchers will examine human esophageal tissues for evidence of stem ceil dysfunction in Barrett's esophagus disease.
Barrett's esophagus is the principal risk factor for esophageal adenocarcinoma, whose incidence in this and other developed nations is increasing at an alarming rate, he said.
In addition, they found that a genetic variant on chromosome 16 that had been previously linked to Barrett's esophagus was also associated with an increased risk of esophageal adenocarcinoma.
The management of high grade dysplasia and early cancer in Barrett's esophagus.